Diabetes and Familial Hypercholesterolemia: Interplay between Lipid and Glucose Metabolism
Open Access
Abstract
Familial hypercholesterolemia (FH) is a genetic disease characterized by high low-density lipoprotein (LDL) cholesterol (LDL-c) concentrations that increase cardiovascular risk and cause premature death. The most frequent cause of the disease is a mutation in the LDL receptor (LDLR) gene. Diabetes is also associated with an increased risk of cardiovascular disease and mortality. People with FH seem to be protected from developing diabetes, whereas cholesterol-lowering treatments such as statins are associated with an increased risk of the disease. One of the hypotheses to explain this is based on the toxicity of LDL particles on insulin-secreting pancreatic β-cells, and their uptake by the latter, mediated by the LDLR. A healthy lifestyle and a relatively low body mass index in people with FH have also been proposed as explanations. Its association with superimposed diabetes modifies the phenotype of FH, both regarding the lipid profile and cardiovascular risk. However, findings regarding the association and interplay between these two diseases are conflicting. The present review summarizes the existing evidence and discusses knowledge gaps on the matter.Keywords
Funding Information
- Instituto de Salud Carlos III (Rio Hortega 2019, INT 21/0032, PI20/00846)
This publication has 172 references indexed in Scilit:
- Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: A cross-sectional studyCytokine, 2012
- Cholesterol induces pancreatic β cell apoptosis through oxidative stress pathwayCell Stress and Chaperones, 2011
- Familial hypercholesterolemia and triglyceride metabolismInternational Journal of Cardiology, 2011
- The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutationsThe Application of Clinical Genetics, 2010
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsThe Lancet, 2010
- The Pathophysiology of Cardiovascular Disease and Diabetes: Beyond Blood Pressure and LipidsDiabetes Spectrum, 2008
- Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysisThe Lancet, 2008
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003
- Familial Hypercholesterolemia in the Finnish North KareliaArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Estimation of the prevalence of familial hypercholesterolaemia in a rural Afrikaner community by direct screening for three Afrikaner founder low density lipoprotein receptor gene mutationsHuman Genetics, 1996